Login
EN
[EN] English
[FR] Français
Login
EN
[EN] English
[FR] Français
Give us feedback
Explore
Search
Special collections
Statistics
News
Help
Start on ORBi
Deposit
Profile
Publication List
Add your ORCID
Tutorials
Legal Information
Training sessions
About
What's ORBi ?
Impact and visibility
Around ORBi
About statistics
About metrics
OAI-PMH
ORBi team
Release Notes
Back
Home
Statistics
Statistics of Rimonabant improves cardiometabolic risk factors in overweight/obese patients with poorly controlled type 2 diabetes (HbA(1c)>= 8%) on monotherapy with metformin or sulfonylureas
Global
Last 12 months
Last 30 days
Contact ORBi